SAN DIEGO -- Invivoscribe announced that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes.

Following a rigorous review by the Clinical Laboratory Evaluation Program (CLEP), the Department of Health has determined that LabPMM meets the required standards and granted approval to offer the FLT3 ITD MRD Assay in New York State. This approval underscores the assay’s robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML.

“This milestone reflects our commitment to improve patient lives with precision diagnostics,” said Jordan Thornes, V.P. Global Clinical Operations at LabPMM®. “With New York state’s approval, we are immediately able to extend access to this important test to clinicians and patients throughout one of the nation’s largest and most rigorously regulated laboratory testing markets.”